# Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain

> **NCT00301847** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 44 (actual)

## Conditions studied

- Kidney Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** sorafenib tosylate

## Key facts

- **NCT ID:** NCT00301847
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2007-06
- **Final completion:** —
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2013-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00301847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00301847, "Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00301847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*